
Sonnet BioTherapeutics Holdings SONN
Quarterly report 2025-Q2
added 08-13-2025
Sonnet BioTherapeutics Holdings EV - Enterprise Value 2011-2026 | SONN
Annual EV - Enterprise Value Sonnet BioTherapeutics Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.23 M | 3.59 M | 5.51 M | -20.9 M | 22.8 M | 6.29 M | 28.6 M | 29 M | 29.8 M | 29.3 M | 2.98 B | 4.56 B | 734 M | 4.16 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.56 B | -20.9 M | 601 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 4.55 | -0.66 % | $ 10.9 B | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Compugen Ltd.
CGEN
|
291 M | $ 2.59 | -5.31 % | $ 242 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 0.91 | 3.25 % | $ 6.69 M | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.33 B | $ 22.57 | -0.44 % | $ 3.74 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.78 | -0.66 % | $ 27.9 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Fennec Pharmaceuticals
FENC
|
167 M | $ 6.33 | -5.52 % | $ 181 M | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Galapagos NV
GLPG
|
82.8 M | $ 27.94 | -1.69 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
27 B | $ 26.19 | -2.24 % | $ 16 B | ||
|
Avenue Therapeutics
ATXI
|
-1.76 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
38.2 M | - | 17.91 % | $ 11.1 M | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 100.7 | -1.33 % | $ 27.2 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Innoviva
INVA
|
1.07 B | $ 23.2 | -2.08 % | $ 1.56 B | ||
|
Innate Pharma S.A.
IPHA
|
259 M | $ 1.45 | 3.57 % | $ 235 M | ||
|
Inventiva S.A.
IVA
|
129 M | $ 4.93 | -1.5 % | $ 138 M | ||
|
Aquestive Therapeutics
AQST
|
540 M | $ 4.06 | -0.73 % | $ 434 M | ||
|
Jaguar Health
JAGX
|
57 M | $ 0.23 | -5.44 % | $ 536 K | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 22.63 | -2.86 % | $ 2.88 B | ||
|
KalVista Pharmaceuticals
KALV
|
944 M | $ 26.73 | 38.9 % | $ 1.44 B | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.42 | -4.39 % | $ 378 M | ||
|
Kamada Ltd.
KMDA
|
252 M | $ 8.14 | -0.09 % | $ 260 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.95 | 1.37 % | $ 4.86 M |